Shuttle Pharmaceuticals Inc Cash Flow Conversion Efficiency
Shuttle Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Shuttle Pharmaceuticals Inc (SHPH) has a cash flow conversion efficiency ratio of -0.722x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.42 Million) by net assets ($3.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Shuttle Pharmaceuticals Inc (2017–2025)
Cash flow conversion efficiency of Shuttle Pharmaceuticals Inc from 2017 to 2025. This chart illustrates how Shuttle Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Shuttle Pharmaceuticals Inc stock quote for real-time trading data and today's change.
Shuttle Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Shuttle Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Shuttle Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shuttle Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Shuttle Pharmaceuticals Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fonix Mobile plc
LSE:FNX
|
1.074x |
|
Entreparticuli
PA:ALENT
|
-4.815x |
|
Siti Networks Limited
NSE:SITINET
|
-0.072x |
|
Korab Resources Ltd
AU:KOR
|
-0.163x |
|
Crest Nicholson Holdings plc
LSE:CRST
|
-0.142x |
|
Chakana Copper Corp
V:PERU
|
-0.248x |
|
ELEMENT NUTR.SCIENCES
F:93X
|
0.014x |
|
HCW Biologics Inc
NASDAQ:HCWB
|
-0.534x |
Annual Cash Flow Conversion Efficiency for Shuttle Pharmaceuticals Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Shuttle Pharmaceuticals Inc from 2017 to 2025. Review SHPH financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.25 Million | $-9.48 Million | -4.206x | +59.30% |
| 2024-12-31 | $709.15K | $-7.33 Million | -10.332x | -650.85% |
| 2023-12-31 | $4.06 Million | $-5.58 Million | -1.376x | -289.81% |
| 2022-12-31 | $7.68 Million | $-2.71 Million | -0.353x | -291.37% |
| 2021-12-31 | $-1.63 Million | $-300.34K | 0.184x | +1062.10% |
| 2020-12-31 | $-1.69 Million | $-26.83K | 0.016x | +100.08% |
| 2018-12-31 | $27.46K | $-566.69K | -20.640x | -2995.31% |
| 2017-12-31 | $-284.35K | $-202.71K | 0.713x | -- |
About Shuttle Pharmaceuticals Inc
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.